Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.72 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783681 | 0.88 | GPR119 (0.54) | GPR119ALDH1A1HPGDPIK3CD | |
| SCHEMBL610359 | 0.87 | GPR119 (0.54) | GPR119ALDH1A1HPGD | |
| SCHEMBL609646 | 0.85 | GPR119 (0.73) | GPR119HDAC4HDAC6 | |
| SCHEMBL17122217 | 0.85 | GPR119 (0.84) | GPR119HDAC4HDAC6HPGDS | |
| SCHEMBL304401 | 0.84 | GPR119 (1.00) | GPR119HDAC4HDAC6 | |
| SCHEMBL4419008 | 0.82 | GPR119 (0.73) | GPR119HDAC4HDAC6PDE4APDE4B | |
| SCHEMBL4416063 | 0.81 | GPR119 (0.78) | GPR119HDAC4HDAC6ALDH1A1HPGD | |
| SCHEMBL4421899 | 0.81 | GPR119 (0.68) | GPR119HDAC4HDAC6ALDH1A1HPGD | |
| SCHEMBL14640607 | 0.81 | GPR119 (0.74) | GPR119HDAC4HDAC6ALDH1A1HPGD | |
| SCHEMBL4420442 | 0.81 | GPR119 (0.77) | GPR119HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | GPR119 1/4885HDAC4 1512/4885HDAC6 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.